Literature DB >> 28501298

ACE2 as therapy for glomerular disease: the devil is in the detail.

Michael J Ross1, Masaomi Nangaku2.   

Abstract

Angiotensin-converting enzyme 2 cleaves angiotensin (Ang) II to Ang(1-7), which antagonizes the deleterious effects of Ang II. In this issue, 2 groups administered angiotensin-converting enzyme 2 in murine models of kidney disease. Angiotensin-converting enzyme 2 did not improve glomerular injury in 2 models of mild diabetic nephropathy but was partially protective in an Alport syndrome model. These discrepant findings may be explained by the inability of angiotensin-converting enzyme 2 to reach the urinary space in the absence of severe proteinuria. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28501298     DOI: 10.1016/j.kint.2017.04.001

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  5 in total

Review 1.  Intrarenal Angiotensin-Converting Enzyme: the Old and the New.

Authors:  Silas Culver; Caixia Li; Helmy M Siragy
Journal:  Curr Hypertens Rep       Date:  2017-09-19       Impact factor: 5.369

2.  Angiotensin-converting enzyme 2 influences pancreatic and renal function in diabetic mice.

Authors:  María José Soler; Marta Riera; Heleia Roca-Ho; Vanesa Palau; Javier Gimeno; Julio Pascual
Journal:  Lab Invest       Date:  2020-05-29       Impact factor: 5.662

3.  Olmesartan Attenuates Kidney Fibrosis in a Murine Model of Alport Syndrome by Suppressing Tubular Expression of TGFβ.

Authors:  Sang Heon Suh; Hong Sang Choi; Chang Seong Kim; In Jin Kim; Seong Kwon Ma; James W Scholey; Soo Wan Kim; Eun Hui Bae
Journal:  Int J Mol Sci       Date:  2019-08-06       Impact factor: 5.923

4.  Novel Variants of Angiotensin Converting Enzyme-2 of Shorter Molecular Size to Target the Kidney Renin Angiotensin System.

Authors:  Jan Wysocki; Arndt Schulze; Daniel Batlle
Journal:  Biomolecules       Date:  2019-12-17

Review 5.  An update on ACE2 amplification and its therapeutic potential.

Authors:  Alonso Marquez; Jan Wysocki; Jay Pandit; Daniel Batlle
Journal:  Acta Physiol (Oxf)       Date:  2020-06-17       Impact factor: 7.523

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.